A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (goserelin acetate implant) 10.8 mg and ZOLADEX® (goserelin acetate implant) 3.6 mg in Chinese Patients with Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

Trial Identifier: D8664R00001
Sponsor: AstraZeneca
NCTID:: NCT03193060
Start Date: September 2017
Primary Completion Date: December 2019
Study Completion Date: December 2019

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China China
China Beijing, China, 100191
China Beijing, China, 100034
China Chengdu, China, 610072
China Foshan, China, 528000
China guangdong, China
China Guangzhou, China, 510120
China Guangzhou, China, 510530
China Hangzhou, China, 310022
China Harbin, China, 150081
China Jinan, China, 250021
China Jinan, China, 250012
China Langfang, China
China Nanjing, China, 210009
China Nanjing, China, 210029
China Ningbo, China, 315000
China Shanghai, China, 200032
China shijiazhuang, China
China Urumqi, China, 830054
China Wu Han, China, 430060
China Wuhan, China, 430022
China Wuhan, China, CN-430030
China Xi'An, China
China Yantai, China, 264000
China zhuhai, China, 519000